Search clinical trials for: MK-6240

Total 1884 results

Merck Sharp & Dohme LLC

Completed

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I)

Clostridium Difficile Infection
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Hypertension
Merck Sharp & Dohme LLC

Recruiting

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Narcolepsy

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Systemic Lupus Erythematosus

Colombia, United States, Canada, Japan, Chile, France, Poland, Spain, Guatemala, Italy, Malaysia, China
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Completed

MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Pulmonary Hypertension

United States, Israel, Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

Alzheimer's Disease
National Human Genome Research Institute (NHGRI)

Completed

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

Proteus Syndrome

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Withdrawn

MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Pneumonia | Coronavirus Disease 2019 (COVID-19) | Hypoxemia
Merck Sharp & Dohme LLC

Completed

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

Postherpetic Neuralgia
Merck Sharp & Dohme LLC

Completed

Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

Diabetic Neuropathy, Painful
Merck Sharp & Dohme LLC

Completed

Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)

Attention Deficit Hyperactivity Disorder
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)

Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

Type 2 Diabetes Mellitus | Chronic Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (MODIFY II)

Clostridium Difficile Infection
Merck Sharp & Dohme LLC

Terminated

Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)

HIV-1 Infection
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

Hepatitis C
Merck Sharp & Dohme LLC

Not yet recruiting

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Steatohepatitis | Metabolic Dysfunction-associated Steatotic Liver Disease | Metabolic Dysfunction-associated Steatohepatitis
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States, China, Poland, Israel, Canada, Chile, Czechia, Estonia, France, Greece, Italy, Korea, Republic of, Norway, Spain, Sweden, Thailand, Turkey
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
Oncoethix GmbH

Completed

A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)

Acute Myeloid Leukemia | Multiple Myeloma | Acute Lymphoblastic Leukemia | Diffuse Large B-cell Lymphoma
Oncoethix GmbH

Terminated

A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

Glioblastoma Multiforme
Merck Sharp & Dohme LLC
ALK-Abelló A/S

Completed

MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

Allergic Rhinitis | Allergic Rhinoconjunctivitis
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Merck Sharp & Dohme LLC

Terminated

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Neoplasms, Advanced
Merck Sharp & Dohme LLC

Completed

Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

Migraine
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

Diabetes Mellitus, Type 2
LUTRONIC Corporation

Completed

Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning

Muscle Stimulation | Fat Necrosis

United States
Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Polycythemia Vera

United States, Australia, United Kingdom
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Essential Thrombocythemia

United States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

Mature B-cell Neoplasms

Japan
Merck Sharp & Dohme LLC
FoxHollow Technologies

Terminated

A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Peripheral Vascular Diseases
ALK-Abelló A/S

Completed

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
Merck Sharp & Dohme LLC
University of Colorado, Denver; Memorial Sloan Kettering Cancer Center; H. Lee... and other collaborators

Completed

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Advanced Non-Small Cell Lung Cancer

Poland, Russian Federation, United States, Australia, Canada, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
Bill & Melinda Gates Medical Research Institute
Merck Sharp & Dohme LLC

Recruiting

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Tuberculosis

United States
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)

Chronic Cough

Japan
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

Chronic Cough

United States, Argentina, Canada, Czechia, Denmark, France, Hungary, Israel, Japan, Korea, Republic of, Peru, Poland, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Oncoethix GmbH

Completed

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castrate-resistant Prostate Cancer | CRPC | NUT Midline Carcinoma | Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation

3

Subscribe